The GLP-1 reference, the same standard of care.
Vayra prescribes branded Wegovy®, Zepbound®, and Mounjaro® for chronic weight management, and Ozempic® for patients with type-2 diabetes — all dispensed by a separately licensed retail/specialty pharmacy partner at the dispensing pharmacy's published cash price. Vayra does not add a markup to medication.
What we prescribe.
Wegovy · semaglutide
FDA-approved for chronic weight management. Once-weekly subcutaneous injection.
ReadZepbound · tirzepatide
FDA-approved for chronic weight management and for obstructive sleep apnea in adults with obesity. Once-weekly subcutaneous injection.
ReadMounjaro · tirzepatide
FDA-approved for type-2 diabetes management. Once-weekly subcutaneous injection.
ReadOzempic · semaglutide
FDA-approved for type-2 diabetes management. Once-weekly subcutaneous injection.
ReadWhy Vayra prescribes branded, not compounded.
Compounded GLP-1 is offered only when a documented clinical difference cannot be met by an FDA-approved product. Cost, insurance denial, and patient preference are not lawful clinical differences.
For the vast majority of patients, the FDA-approved branded product — Wegovy®, Zepbound®, or Mounjaro® (and Ozempic® where T2D is the indication) — is the right standard of care. Vayra does not prescribe compounded semaglutide or compounded tirzepatide as a default, and we do not sell convenience packages that route patients away from the evidence base.
Pricing varies by brand, dose, and dispensing pharmacy. Your Vayra membership covers your clinical relationship — medication is billed separately by the dispensing pharmacy at its published cash price, and the exact figure for your visit appears in your portal before you authorize routing.
Begin a documented physician visit.
Continuity is a priority — you will see the same physician whenever clinically possible. 45-min initial visit, 30-min monthly check-ins, unlimited secure messaging. Private clinical practice, no insurance billing.